Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
The U.S. Food and Drug Administration announced on 30 June that it approved Tregzi for improving chronic graft-versus-host disease-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem-cell transplantation.
FDA describes Tregzi as a donor-derived cellular immunotherapy composed of purified hematopoietic stem and progenitor cells, regulatory T cells and conventional T cells, all derived from an 8/8 HLA-matched related or unrelated donor.
The agency says safety and effectiveness were established in PRECISION-T, a randomized clinical trial of 187 adult patients with blood cancers including acute leukemia and myelodysplastic syndrome. The primary endpoint was chronic GVHD-free survival within two years after transplantation.
According to FDA, 78% of patients receiving Tregzi achieved chronic GVHD-free survival at one year, compared with 38.4% receiving a standard transplant. FDA also reports serious chronic GVHD within one year in 12.6% of Tregzi patients after accounting for death as a competing risk, compared with 44% in the standard-transplant group.
FDA says observed side effects were generally consistent with stem-cell transplantation, most commonly infections, and that no severe infusion reaction or graft failure was observed during the study period. The application received Orphan Drug and Regenerative Medicine Advanced Therapy designations.
Sourcing note: Approval status, indication, trial size, reported endpoint results and designations are confirmed by FDA. This article does not independently review the full prescribing information or individual patient-level data; clinical use still depends on specialist assessment and the complete label.
Why It Matters
The approval adds a regulated cellular-therapy option to a high-risk transplant setting where controlling graft-versus-host disease is central to long-term outcomes. It also shows how engineered donor-cell products are moving from oncology trials into transplantation support.
What to Watch
Watch the final label, manufacturing capacity, transplant-center uptake, post-marketing safety signals, payer coverage and whether similar regulatory T-cell approaches expand into other transplant or immune-tolerance settings.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDACell TherapyBlood CancerGVHDBiologics